Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: May 2011

Chapter 10 - Antiangiogenic agents for endometriosis

Summary

This chapter addresses the controversies surrounding the impact and surgical management of hydrosalpinges and uterine leiomyoma on in vitro fertilization (IVF) cycle outcome. Evidence accumulated over the last 15 years suggests that either unilateral or bilateral hydrosalpinges may exert deleterious effects on IVF cycle outcome. Hydrosalpinx fluid may have a direct embryotoxic effect and may also inhibit fertilization. This deleterious effect may be mediated by the presence of inflammatory cytokines present within hydrosalpinx fluid. Several groups have reported that only large hydrosalpinges, visible on ultrasound, resulted in reduced implantation and pregnancy rates. The impact of uterine leiomyomata specifically on the outcome of assisted reproductive technologies has been evaluated with conflicting results. Evaluation of the uterine cavity by hysteroscopy or sonohysterography should be a routine part of the pre-cycle evaluation. The accuracy of routine ultrasound evaluation and hysterosalpingography is more limited.

References

1. MahmoodTA, TempletonA. Prevalence and genesis of endometriosis. Hum Reprod 1991;6:544–9.
2. MatorrasR, RodiquezF, PijoanJI, et al. Epidemiology of endometriosis in infertile women. Fertil Steril 1995;63:34–8.
3. RawsonJM. Prevalence of endometriosis in asymptomatic women. J Reprod Med 1991;36:513–15.
4. WallerKG, LindsayP, CurtisP, ShawRW. The prevalence of endometriosis in women with infertile partners. Eur J Obstet Gynecol Reprod Biol 1993;48:135–9.
5. LauferMR, GoiteinL, BushM, CramerDW, EmansSJ. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997;10:199–202.
6. StanfordEJ, KoziolJ, FengA. The prevalence of interstitial cystitis, endometriosis, adhesions, and vulvar pain in women with chronic pelvic pain. J Minim Invasive Gynecol 2005;12:43–9.
7. GaoX, YehYC, OutleyJ, et al. Health-related quality of life burden of women with endometriosis: a literature review. Curr Med Res Opin 2006;22:1787–97.
8. BianconiL, HummelshojL, CocciaME, et al. Recognizing endometriosis as a social disease: the European Union-encouraged Italian Senate approach. Fertil Steril 2007;88:1285–7.
9. FordJ, EnglishJ, MilesWA, GiannopoulosT. Pain, quality of life and complications following the radical resection of rectovaginal endometriosis. BJOG 2004;111:353–6.
10. GuoSW. Recurrence of endometriosis and its control. Hum Reprod Update 2009;15:441–61.
11. GiudiceLC, KaoLC. Endometriosis. Lancet 2004;364:1789–99.
12. HughesEG, DedorkowDM, CollinsJA. A quantitative overview of controlled trials in endometriosis-associated infertility. Fertil Steril 1993;59:963–76.
13. MarcouxS, MaheuxR, BedrubS. Laparoscopic surgery in infertile women with minimal or mild endometriosis: Canadian Collaborative Group in Endometriosis. N Engl J Med 1997;337:217–22.
14. ParazziniF. Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial. Hum Reprod 1999;14:1332–4.
15. Garcia-VelascoJA, MahutteNG, CoronaJ, et al. Removal of endometriomas before in vitro fertilization does not improve fertility outcomes: a matched, case-control study. Fertil Steril 2004;81:1194–7.
16. De BoerEJ, den TomkelaarI, te VeldeER, BurgerCW, van LeeuwenFE and OMEGA project group. Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod 2003;18:1544–52.
17. BulunSE, YangS, FangZ, et al. Estrogen production and metabolism in endometriosis. Ann N Y Acad Sci 2002;955:75–85.
18. RiceVM. Conventional medical therapies for endometriosis. Ann N Y Acad Sci 2002;955:343–52.
19. GibbonsWE. Management of endometriosis in fertility patients. Fertil Steril 2004;81:1204–5.
20. SagsveenM, FarmerJE, PrenticeA, BreezeA. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst Rev 2003;CD001297.
21. VercelliniP, TrespidiL, ColomboA. A gonadotropin releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993;60:75–9.
22. OliveDL. Medical therapy of endometriosis. Semin Reprod Med 2003;21:209–22.
23. KennedySH, WilliamsIA, BrodribbJ, BarlowDH, ShawRW. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990;53:998–1003.
24. BarbieriRL, EvansS, KisterRW. Danazol in the treatment of endometriosis: analysis of 100 cases with a 4-year follow-up. Fertil Steril 1982;37:737–46.
25. KauppilaA. Changing concepts of medical treatment of endometriosis. Acta Obstet Gynecol Scand 1993;72:324–36.
26. FedeleL, BerlandaN. Emerging drugs for endometriosis. Expert Opin Emerg Drugs 2004;9:167–77.
27. LucianoAA. Danazol treatment of endometriosis-associated pain. J Minim Invasive Gynecol 2006;13:523–4.
28. VercelliniP, CortesiI, CrosignaniPG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 1997;68:393–401.
29. VercelliniP, CrosignaniPG, SomiglianaE, et al. Medical treatment for rectovaginal endometriosis: what is the evidence? Hum Reprod 2009;24:2504–14.
30. AttarE, BulunSE. Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 2006;85:1307–18.
31. DmowskiWP, GebelHM, RawlinsRG. Immunologic aspects of endometriosis. Obstet Gynecol Clin North Am 1989;16:93–103.
32. OsteenKG, Sierra-RiveraE. Does disruption of immune and endocrine systems by environmental toxins contribute to development of endometriosis? Semin Reprod Endocrinol 1997;15:301–8.
33. TaylorRN, LebovicDI, MuellerMD. Angiogenic factors in endometriosis. Ann NY Acad Sci 2002;955:89–100.
34. DmowskiWP, DingJ, ShenJ, et al. Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. Hum Reprod 2001;16:1802–8.
35. BeliardA, NoelA, FoidartJM. Reduction of apoptosis and proliferation in endometriosis. Fertil Steril 2004;82:80–5.
36. NisolleM, Casanas-RouxF, AnafV, MineJM, DonnezJ. Morphometric study of the stromal vascularization in peritoneal endometriosis. Fertil Steril 1993;59:681–4.
37. NisolleM, DonnezJ. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. Fertil Steril 1997;68:585–96.
38. HayesEC, RockJA. COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv 2002;57:768–80.
39. HillJA, FarisHM, SchiffI, AndersonDJ. Characterization of leukocyte subpopulations in the peritoneal fluid of women with endometriosis. Fertil Steril 1988;50:216–22.
40. LaschkeMW, MengerMD. In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis. Hum Reprod Update 2007;13:331–42.
41. GroothuisPG, NapAW, WinterhagerE, GrümmerR. Vascular development in endometriosis. Angiogenesis 2005;8:147–56.
42. BeckerCM, D’AmatoRJ. Angiogenesis and antiangiogenic therapy in endometriosis. Microvasc Res 2007;74:121–30.
43. KoninckxPR, KennedySH, BarlowDH. Endometriotic disease: the role of peritoneal fluid. Hum Reprod Update 1998;4:741–51.
44. GargettC, WestonG, RogersP. Mechanisms and regulation of endometrial angiogenesis. Reprod Med Rev 2002;10:45–61.
45. BenjaminLE, KeshetE. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 1997;94:8761–6.
46. KeckPJ, HauserSD, KriviG, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309–12.
47. SengerDR, PerruzziCA, FederJ, DvorakHF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629–32.
48. WatanabeY, LeeSW, DetmarM, AjiokaI, DvorakHF. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene 1997;14:2025–32.
49. WeiMH, PopescuNC, LermanMI, MerrillMJ, ZimonjicDB. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet 1996;97:794–9.
50. NeufeldG, CohenT, GengrinovitchS, PoltorakZ. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22.
51. WatkinsRH, D’AngioCT, RyanRM, PatelA, ManiscalcoWM. Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. Am J Physiol 1999;276:858–67.
52. MustonenT, AlitaloK. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995;129:895–8.
53. ShibuyaM. Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv Cancer Res 1995;67:281–316.
54. ShalabyF, RossantJ, YamaguchiTP, et al. Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62–6.
55. VerheulHM, HoekmanK, JornaAS, SmitEF, PinedoHM. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist 2000;5:45–50.
56. NapAW, DunselmanGA, GriffioenAW, et al. Angiostatic agents prevent the development of endometriosis-like lesions in the chicken chorioallantoic membrane. Fertil Steril 2005;83:793–5.
57. MachadoDE, AbraoMS, BerardoPT, TakiyaCM, NasciuttiLE. Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum. Fertil Steril 2008;90:148–55.
58. TaylorRN, MuellerMD. Anti-angiogenic treatment of endometriosis: biochemical aspects. Gynecol Obstet Invest 2004;57:54–6.
59. DabrosinC, GyorffyS, MargettsP, RossC, GauldieJ. Therapeutic Effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 2002; 909–18.
60. HullML, Charnock-JonesDS, ChanCL, et al. Antiangiogenic agents are effective inhibitors of endometriosis. J Clin Endocrinol Metab 2003;88:2889–99.
61. BeckerCM, SampsonDA, RupnickMD, et al. Endostatin inhibits the growth of endometriotic lesions but does not affect fertility. Fertil Steril 2005;84:1144–55.
62. LaschkeMW, ElitzschA, ScheuerC, et al. Rapamycin induces regression of endometriotic lesions by inhibiting neovascularization and cell proliferation. Br J Pharmacol 2006;149:137–44.
63. LaschkeMW, ElitzschA, VollmarB, VajkoczyP, MengerMD. Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions. Hum Reprod 2006;21:262–8.
64. Novella-MaestreE, CardaC, NogueraI, et al. Dopamine agonist administration causes a reduction in endometrial implants through modulation of angiogenesis in experimentally induced endometriosis. Human Reprod 2009;24:1025–35.
65. MönckedieckV, SanneckeC, HusenB, et al. Progestins inhibit expression of MMPs and of angiogenic factors in human ectopic endometrial lesions in a mouse model. Mol Hum Reprod 2009;15:633–43.
66. BeckerCM, SampsonDA, ShortSA, et al. Short synthetic endostatin peptides inhibit endothelial migration in vitro and endometriosis in a mouse model. Fertil Steril 2006;85:71–7.
67. ParkA, ChangP, FerinM, XiaoE, ZeitounK. Inhibition of endometriosis development in Rhesus monkeys by blocking VEGF receptor: a novel treatment for endometriosis. Fertil Steril 2004;82:S71.
68. PeetersLL, VigneJL, TeeMK, et al. PPARgamma represses VEGF expression in human endometrial cells: implications for uterine angiogenesis. Angiogenesis 2005;8:373–9.
69. LebovicDI, MwendaJM, ChaiDC, et al. PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 2007;88:1108–19.
70. MatsuzakiS, MurakamiT, UeharaS, et al. Erythropoietin concentrations are elevated in the peritoneal fluid of women with endometriosis. Hum Reprod 2001;16:945–8.
71. KlauberN, ParangiS, FlynnE, HamelE, D’AmatoRJ. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81–6.
72. PauliSA, TangH, WangJ, et al. The vascular endothelial growth factor (VEGF)/VEGF receptor 2 pathway is critical for blood vessel survival in corpora lutea of pregnancy in the rodent. Endocrinology 2005;146:1301–11.
73. McCarthyM. Angiogenesis drug promising for metastatic colorectal cancer. Lancet 2003;361:1959.
74. LienS, LowmanHB. Therapeutic anti-VEGF antibodies. Handb Exp Pharmacol 2008;181:131–50.
75. ValachisA, PolyzosNP, PatsopoulosNA, et al. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat 2010;122:1–7.
76. ViaLE, Gore-LangtonRE, PludaJM. Current clinical trials administering the antiangiogenesis agent SU5416. Oncology 2000;14:1312–23.
77. BasuS, NagyJA, PalS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 2001;7:569–74.
78. GomezR, Gonzalez-IzquierdoM, ZimmermannRC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400–11.
79. AlvarezC, Martí-BonmatíL, Novella-MaestreE, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007;92:2931–7.
80. GillamMP, MolitchME, LombardiG, ColaoA. Advances in the treatment of prolactinomas. Endocr Rev 2006;27:485–534.
81. ColaoA, Di SarnoA, GuerraE, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 2007;67:426–33.
82. BuhendwaL, ZachariahR, TeckR, et al. Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi. Trop Doct 2008;38:30–2.
83. RobertE, MusattiL, PiscitelliG, FerrariCI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333–7.
84. RicciE, ParazziniF, MottaT, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16:791–3.
85. SchadeR, AndersohnF, SuissaS, HaverkampW, GarbeE. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29–38.
86. ZanettiniR, AntoniniA, GattoG, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007;356:39–46.